Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Pyrotinib in HER2+ Advanced Breast Cancer
NCT07180082Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pyrotinib in breast cancer (2 arms). Primary endpoint: Overall Response Rate at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07180082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180082.